Jun-Ting Tang, Yu-Liang Qin, Wei-Jia Zhao, Ying Tu, Dong-Jie Sun
{"title":"Abrocitinib alleviates the symptoms of Netherton syndrome and is well tolerated.","authors":"Jun-Ting Tang, Yu-Liang Qin, Wei-Jia Zhao, Ying Tu, Dong-Jie Sun","doi":"10.1080/09546634.2024.2447883","DOIUrl":"10.1080/09546634.2024.2447883","url":null,"abstract":"<p><strong>Purpose: </strong>To investigate the potential genetic basis of Netherton syndrome (NS) through first- and second-generation DNA sequencing techniques. Additionally, we evaluated the therapeutic efficacy of Abrocitinib in NS patients.</p><p><strong>Materials and methods: </strong>We conducted whole-exome sequencing analysis on a pedigree comprising one affected individual with NS. Subsequently, the identified patient was treated with Abrocitinib, and clinical improvements in cutaneous manifestations were systematically assessed.</p><p><strong>Results: </strong>Genetic analysis revealed that the patient harbored compound heterozygous mutations in the SPINK5 gene, including a missense mutation in exon 26 (c.2475G > T, p.Trp825Cys). Following six months of Abrocitinib therapy, the patient exhibited marked improvement in skin rash and overall disease severity.</p><p><strong>Conclusions: </strong>Our findings suggest that SPINK5 missense mutations may contribute to the pathogenesis of NS. Furthermore, Abrocitinib demonstrates promising therapeutic potential in the management of NS, warranting further investigation in larger clinical cohorts.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2447883"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143756896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ilaria Trave, Ilaria Salvi, Giorgio Battaglia, Alice Vischi, Aurora Parodi, Emanuele Cozzani
{"title":"Frequency and clinical features of disease flares in patients with atopic dermatitis treated with dupilumab.","authors":"Ilaria Trave, Ilaria Salvi, Giorgio Battaglia, Alice Vischi, Aurora Parodi, Emanuele Cozzani","doi":"10.1080/09546634.2025.2495831","DOIUrl":"10.1080/09546634.2025.2495831","url":null,"abstract":"<p><strong>Background: </strong>Dupilumab, an interleukin 4 (IL-4) receptor α-antagonist approved for the treatment of atopic dermatitis, is considered effective in preventing disease recurrences. However, the incidence and characteristics od atopic dermatitis flares during treatment with dupilumab in a real-life setting have not been described in the literature.</p><p><strong>Objective: </strong>This study aims to evaluate the prevalence of disease flares in patients in treatment with dupilumab and to describe the features of flares in our study population.</p><p><strong>Methods: </strong>We conducted a retrospective observational study in which we collected demographic and clinical data on adult patients with a diagnosis of severe atopic dermatitis in treatment with dupilumab for a minimum of six months, who reached EASI75 within six months of treatment initiation.</p><p><strong>Results: </strong>Ninety-nine patients were enrolled. Recurrences were recorded for 38.4% of patients and 7.1% developed a second recurrence. The EASI at recurrence was always lower than the EASI before treatment initiation. The localization of disease at head and neck before treatment was associated to the same localization of disease at the first recurrence (<i>p</i> = 0.011). The risk of recurrence was associated to the baseline EASI score (<i>p</i> = 0.005). The presence of dupilumab-related conjunctivitis was significantly associated to recurrences (<i>p</i> = 0.02).</p><p><strong>Conclusions: </strong>Treatment with dupilumab does not exclude the risk of a relapse, which can be estimated around 50% within a timespan of three years. In the most cases, flares should not be regarded as treatment failures, and can be easily managed with additional treatment.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2495831"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144033242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Successful treatment of Kimura's disease with dupilumab and review of dupilumab in treating eosinophilic dermatoses.","authors":"Yunhong Zheng, Suju Luo","doi":"10.1080/09546634.2024.2449153","DOIUrl":"https://doi.org/10.1080/09546634.2024.2449153","url":null,"abstract":"","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2449153"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142960826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Meiying Tao, Tingting Gao, Lili Zhi, Naiqing Cao, Haotian Liu
{"title":"Rapid improvement of kimura disease with dupilumab in a patient with suboptimal response to mepolizumab: a case report.","authors":"Meiying Tao, Tingting Gao, Lili Zhi, Naiqing Cao, Haotian Liu","doi":"10.1080/09546634.2025.2486668","DOIUrl":"https://doi.org/10.1080/09546634.2025.2486668","url":null,"abstract":"","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2486668"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143766278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
D Orsini, D Graceffa, M Burlando, A Campanati, E Campione, C Guarneri, A Narcisi, P Pella, P Romita, M Travaglini, L Zichichi, L M H Arancio, G Baggini, R Balestri, L Bianchi, A M G Brunasso, A E Cagni, Giacomo Caldarola, G Calianno, A Carpentieri, M Carriero, A Carugno, F Cona, A Costanzo, E Cozzani, Giacomo Dal Bello, Giovanni Carlo Lazzaro Danzuso, A Dattola, A Di Tano, F Diotallevi, M Donnarumma, E De Col, M Esposito, C S Fiorella, M Galluzzo, F Graziola, M Licciardello, A Legori, P Malagoli, Federica Mola, G Moretta, A Muracchioli, A Musumeci, M L Musumeci, G Pagnanelli, V Panasiti, E Provenzano, D Rizzo, M Rubatto, Oriele Sarno, D Strippoli, F Vaira, M C Fargnoli
{"title":"Effectiveness, speed of action and safety of brodalumab in elderly psoriasis patients: a multicenter real-world study - IL PSO (Italian Landscape Psoriasis).","authors":"D Orsini, D Graceffa, M Burlando, A Campanati, E Campione, C Guarneri, A Narcisi, P Pella, P Romita, M Travaglini, L Zichichi, L M H Arancio, G Baggini, R Balestri, L Bianchi, A M G Brunasso, A E Cagni, Giacomo Caldarola, G Calianno, A Carpentieri, M Carriero, A Carugno, F Cona, A Costanzo, E Cozzani, Giacomo Dal Bello, Giovanni Carlo Lazzaro Danzuso, A Dattola, A Di Tano, F Diotallevi, M Donnarumma, E De Col, M Esposito, C S Fiorella, M Galluzzo, F Graziola, M Licciardello, A Legori, P Malagoli, Federica Mola, G Moretta, A Muracchioli, A Musumeci, M L Musumeci, G Pagnanelli, V Panasiti, E Provenzano, D Rizzo, M Rubatto, Oriele Sarno, D Strippoli, F Vaira, M C Fargnoli","doi":"10.1080/09546634.2025.2452948","DOIUrl":"https://doi.org/10.1080/09546634.2025.2452948","url":null,"abstract":"","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2452948"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143366174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Tofacitinib as a promising treatment for refractory erythroderma-like Hailey-Hailey disease.","authors":"Huaye Bao, Keyi Yu, Feilong An, Xin-Gang Wu","doi":"10.1080/09546634.2025.2493936","DOIUrl":"https://doi.org/10.1080/09546634.2025.2493936","url":null,"abstract":"<p><strong>Purpose: </strong>Hailey-Hailey disease (HHD), a rare autosomal dominant blistering disorder predominantly affecting intertriginous areas, is characterized by chronic relapsing courses that cause substantial morbidity. Despite multiple available therapeutic modalities, management of refractory cases remains challenging.</p><p><strong>Materials and methods: </strong>This case report details a 67-year-old male with severe erythroderma-like HHD, whose genetic analysis revealed a heterozygous nonsense mutation (c.1774C > T) in the <i>ATP2C1</i> gene. Following conventional therapies, the patient developed treatment-related complications. Therefore, oral tofacitinib was administered as an alternative treatment.</p><p><strong>Results: </strong>The patient achieved marked clinical improvement post-tofacitinib administration, with no treatment-emergent adverse events.</p><p><strong>Conclusions: </strong>This case indicates that tofacitinib may serve as a promising therapeutic option for refractory erythroderma-like HHD, particularly in cases linked to <i>ATP2C1</i> mutations.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2493936"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144048065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Linda Stein Gold, James Del Rosso, Benjamin D Ehst, Matthew J Zirwas, Lawrence J Green, Philip M Brown, David S Rubenstein, Stephen C Piscitelli, Anna M Tallman
{"title":"Tapinarof cream 1% once daily was well tolerated in adults and children with atopic dermatitis in two phase 3 randomized trials.","authors":"Linda Stein Gold, James Del Rosso, Benjamin D Ehst, Matthew J Zirwas, Lawrence J Green, Philip M Brown, David S Rubenstein, Stephen C Piscitelli, Anna M Tallman","doi":"10.1080/09546634.2024.2444489","DOIUrl":"10.1080/09546634.2024.2444489","url":null,"abstract":"<p><p><b>Background:</b> Tapinarof cream 1% once daily (QD) demonstrated significant efficacy in patients down to age 2 years with atopic dermatitis (AD) in the ADORING 1 and 2 phase 3 trials. We report local tolerability outcomes.<b>Methods:</b> Patients received Tapinarof or vehicle cream QD for 8 weeks. Tolerability was evaluated using patient/parent/caregiver and investigator 5-point Local Tolerability Scales (LTS). Investigators assessed tolerability for sensitive skin areas, including face/neck.<b>Results:</b> 813 patients were randomized (∼80% pediatric). Mean pretreatment baseline overall LTS scores were similar across groups and trials: 1.0-1.9 (patient-assessed) indicating slight burning/stinging and itching; and 0.3-0.6 (investigator-assessed) indicating no-to-minimal irritation. Tapinarof was well tolerated with improvement from pretreatment baseline and no-to-minimal burning/stinging and itching from first application through Week 8 (patient-reported): mean Week 8 LTS scores were 0.2-0.4 (burning/stinging) and 0.6-0.8 (itching). Investigators reported improvement from pretreatment baseline with no-to-minimal irritation (dryness/erythema/peeling) from first Tapinarof application through Week 8 (mean LTS scores: 0.2 and 0.1 in ADORING 1 and 2, respectively). Across sensitive skin, investigators reported no-to-minimal irritation from first application through Week 8 (mean scores [Tapinarof versus vehicle]: 0-0.3 versus 0-1.0).<b>Conclusion:</b> Tapinarof was well tolerated locally from first application through Week 8, including on sensitive skin areas.</p><p><p><b>Clinicaltrials.gov numbers</b> NCT05014568, NCT05032859.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2444489"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143056176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Georgia Marquez-Grap, Allison Kranyak, Nicholas Brownstone, John Koo
{"title":"Can pimozide kill parasites? Surprisingly, the most honest answer is 'yes'.","authors":"Georgia Marquez-Grap, Allison Kranyak, Nicholas Brownstone, John Koo","doi":"10.1080/09546634.2025.2466635","DOIUrl":"10.1080/09546634.2025.2466635","url":null,"abstract":"<p><p><b>Purpose:</b> One of the most well-known medications for treating delusional infestation (DI) is pimozide. Many patients may be reluctant to initiate treatment unless a medication has anti-pathogenic properties, as they feel otherwise it does not address their concerns regarding infestation. In this article, we explore the evidence that pimozide has a range of antipathogenic effects and how this fact can aid in patient care.</p><p><p><b>Materials and methods:</b> A scoping literature review was performed using The National Library of Medicine (PubMed). The search terms used were pimozide AND anti-microbial OR anti-bacterial OR anti-infective. All relevant articles were reviewed up to September 2024.</p><p><p><b>Results:</b> Our findings show that pimozide has antibacterial and antiparasitic effects through several unique mechanisms. Additionally, several older first-generation antipsychotics also have demonstrated anti-pathogenic properties. While the studies identified are entirely <i>in vitro</i>, the potential antipathogenic effects of pimozide may be pivotal to patients with DI as they make the critical decision to accept or reject treatment.</p><p><p><b>Conclusion:</b> With adequate disclaimers that pimozide's therapeutic efficacy may not have to do with its anti-pathogen profile, the evidence that pimozide has anti-pathogenic properties may enable dermatology providers to strengthen their therapeutic approach and alliance with patients with DI and make life-changing therapy more acceptable to the patient.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2466635"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143485223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mario Valenti, Luciano Ibba, Sara Di Giulio, Luigi Gargiulo, Piergiorgio Malagoli, Anna Balato, Carlo G Carrera, Paolo Dapavo, Eugenia V Di Brizzi, Valentina Dini, Francesca Gaiani, Francesco Loconsole, Angelo V Marzano, Matteo Megna, Alessandra Michelucci, Luca Potestio, Simone Ribero, Antonio Costanzo, Alessandra Narcisi
{"title":"Safety of interleukin inhibitors in patients with plaque psoriasis and history of neoplasms: a multicenter retrospective study - IL PSO (Italian landscape psoriasis).","authors":"Mario Valenti, Luciano Ibba, Sara Di Giulio, Luigi Gargiulo, Piergiorgio Malagoli, Anna Balato, Carlo G Carrera, Paolo Dapavo, Eugenia V Di Brizzi, Valentina Dini, Francesca Gaiani, Francesco Loconsole, Angelo V Marzano, Matteo Megna, Alessandra Michelucci, Luca Potestio, Simone Ribero, Antonio Costanzo, Alessandra Narcisi","doi":"10.1080/09546634.2025.2456532","DOIUrl":"10.1080/09546634.2025.2456532","url":null,"abstract":"<p><p><b>Background:</b> Interleukin (IL) inhibitors are increasingly used in the management of moderate-to-severe plaque psoriasis. However, their use in patients with a history of cancer is debated.</p><p><p><b>Objective:</b> We conducted a multicenter retrospective study across nine Italian Dermatology Units to assess the real-world effectiveness and safety of IL inhibitors (IL-23, IL-17, IL-12/23) in 136 oncological patients with moderate-to-severe plaque psoriasis. In particular, we evaluated 116 patients who developed the neoplasm before starting the biologic with a mean time from diagnosis of neoplasia to the first biologic dose of 8.31 years. We also assessed 20 patients who received a diagnosis of neoplasm during treatment with IL inhibitors after a mean time of 2.41 years from the start of the biologic with a cumulative incidence of 3.06 per 1000 individuals.</p><p><p><b>Results:</b> Three patients experienced neoplasm recurrence during treatment with IL inhibitors, which led to the discontinuation of these drugs. In our study, biologics have demonstrated safety and effectiveness as treatment options for patients with both a history of neoplasm and those with concurrent tumors. However, further investigation is needed, particularly through larger and longer multicenter studies.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2456532"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143054175","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
